The results of our study suggests that patients with HER2+ BC subtyped into Cluster C have a high frequency of TP53 mutations, whereas the biological functional abnormalities produced by mutations in Cluster A and Cluster B were primarily centered in the TP53 signaling pathway. This evidence concerns the gene ERBB2 and breast cancer.